ANI Pharmaceuticals (BSFA) Income Statement
ANI Pharmaceuticals Income Statement
Last quarter (Q2 2026), ANI Pharmaceuticals's total revenue was $266.04M, an increase of 25.87% from the same quarter last year. In Q2, ANI Pharmaceuticals's net income was $24.71M. See ANI Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 883.37M | $ 614.38M | $ 486.82M | $ 316.38M | $ 216.14M | |
| $ 450.64M | $ 364.17M | $ 305.30M | $ 177.60M | $ 115.53M | |
| $ 369.41M | $ 363.58M | $ 258.33M | $ 212.88M | $ 155.32M | |
| Depreciation and Amortization | $ 91.42M | $ 67.73M | $ 59.79M | $ 59.65M | $ 47.25M |
| $ 207.27M | $ 63.12M | $ 106.60M | $ 25.04M | $ 3.12M | |
| $ 81.23M | $ 584.00K | $ 46.97M | $ -35.28M | $ -39.79M | |
| $ 14.56M | $ -22.80M | $ -27.10M | $ -27.38M | $ -16.27M | |
| $ 95.79M | $ -22.21M | $ 19.87M | $ -62.66M | $ -56.06M | |
| $ 78.34M | $ -18.52M | $ 18.78M | $ -47.90M | $ -42.60M | |
| Per Share Metrics | |||||
| Basic EPS | $ 3.50 | $ -1.04 | $ 0.95 | $ -3.05 | $ -3.40 |
| Diluted EPS | $ 3.32 | $ -1.04 | $ 0.94 | $ -3.05 | $ -3.40 |
| Weighted Average Shares Outstanding | 20.05M | 19.32M | 18.00M | 16.26M | 12.60M |
| Weighted Average Shares Outstanding (Diluted) | 21.23M | 19.32M | 18.19M | 16.26M | 12.60M |
Currency in USD
